Literature DB >> 25330748

Response: physostigmine may not be the only option for treating anticholinergic syndrome.

Thomas Pluim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25330748      PMCID： PMC4371040          DOI： 10.1007/s13181-014-0443-y

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN： 1556-9039


× No keyword cloud information.
  6 in total

Review 1.  Assessing physostigmine's contraindication in cyclic antidepressant ingestions.

Authors:  Jeffrey R Suchard
Journal:  J Emerg Med       Date:  2003-08       Impact factor: 1.484

2.  Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care.

Authors:  Richard C Dart; Stephen W Borron; E Martin Caravati; Daniel J Cobaugh; Steven C Curry; Jay L Falk; Lewis Goldfrank; Susan E Gorman; Stephen Groft; Kennon Heard; Ken Miller; Kent R Olson; Gerald O'Malley; Donna Seger; Steven A Seifert; Marco L A Sivilotti; Tammi Schaeffer; Anthony J Tomassoni; Robert Wise; Gregory M Bogdan; Mohammed Alhelail; Jennie Buchanan; Jason Hoppe; Eric Lavonas; Sara Mlynarchek; Dong-Haur Phua; Sean Rhyee; Shawn Varney; Amy Zosel
Journal:  Ann Emerg Med       Date:  2009-05-05       Impact factor: 5.721

3.  Physostigmine is the antidote for anticholinergic syndrome.

Authors:  Philip W Moore; J J Rasimas; J W Donovan
Journal:  J Med Toxicol       Date:  2015-03

4.  Novel use of dexmedetomidine for the treatment of anticholinergic toxidrome.

Authors:  Ashley Walker; Andrew Delle Donne; Elizabeth Douglas; Kristine Spicer; Thomas Pluim
Journal:  J Med Toxicol       Date:  2014-12

5.  Physostigmine as an antidote.

Authors:  M Stilson; K Kelly; J Suchard
Journal:  Cal J Emerg Med       Date:  2001-10

Review 6.  Physostigmine: is there a role for this antidote in pediatric poisonings?

Authors:  Nan Frascogna
Journal:  Curr Opin Pediatr       Date:  2007-04       Impact factor: 2.856
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.